Fox Chase Cancer Center Welcomes Aitziber Buque Martinez

dr. martinex 1200x628 px
Aitziber Buque Martinez, PhD, has joined Fox Chase as an Assistant Professor in the Cancer Signaling and Microenvironment Research Program.

PHILADELPHIA (August 2, 2024) — Fox Chase Cancer Center is pleased to announce the hiring of Aitziber Buque Martinez, PhD, as an Assistant Professor in the Cancer Signaling and Microenvironment Research Program

Prior to joining Fox Chase, Martinez was an instructor of cell biology in the Department of Radiation Oncology at the Weill Cornell Medical College in New York. 

“We are very excited to have Dr. Martinez join the Fox Chase and Temple family. We look forward to her adding her considerable expertise on questioning how the immune system is altered during tumor development, as well as under the effect of various metabolic disorders, to our thriving research programs,” said Edna “Eti” Cukierman, PhD, Co-Leader of the Cancer Signaling and Microenvironment Research Program and Co-Director of The Marvin and Concetta Greenberg Pancreatic Cancer Institute.

Martinez received her undergraduate degree in biochemistry from the University of the Basque Country in Leioa, Spain. She also earned a master’s degree in bioinformatics and computational biology from The Complutense University of Madrid, as well as a master’s in cellular biology and neoplastic diseases from the University of the Basque Country. Martinez earned her doctoral degree in biomedicine at the Biocruces Research Institute – University of the Basque Country. 

She completed a postdoctoral fellowship at the Gustave Roussy Comprehensive Cancer Center in Paris, where she studied in the Apoptosis, Cancer, and Immunity Laboratory. She then went on to become a postdoctoral associate in the Department of Radiation Oncology at the Weill Cornell Medical College, before becoming an instructor of cell biology there. 

She has published more than 60 articles in peer-reviewed journals and has served as co-editor of Methods in Cell Biology

Martinez is currently a member of the Society for Immunotherapy of Cancer (SITC), the Early Career Scientist Committee at SITC, the Spanish Scientist in USA Society, the Spanish Society for Biochemistry and Molecular Biology, and the American Association for Cancer Research.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427